课题基金 / 基金详情

Large-scale integrative studies of risk factors in coronary heart disease: from discovery to application

Large-scale integrative studies of risk factors in coronary heart disease: from discovery to application
冠心病危险因素的大规模综合研究:从发现到应用
批准号:
MR/L003120/1
负责人:
John Danesh
金额:
$257.11万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2013
资助国家:
英国
项目状态:
已结题
起止时间:
2013 至 --

项目摘要

项目成果

John Danesh的其他基金

相似基金

相关文献

中文摘要
翻译
如果医学研究能够可靠地证明一个特定的因素与心脏病有关,那么这可能对疾病的预测和预防有重要的意义,例如,现在的情况是测量和修改血液中的低密度脂蛋白(“坏”)胆固醇水平。不幸的是,尝试使用传统方法来识别与心脏病有因果关系的风险因素,往往会在新药试验中导致代价高昂的失败。同样,在对传统方法进行渐进式修改后,在预测心脏病方面也只取得了适度的改进。我们的研究计划将分子测量的精确性与大规模人口健康研究的力量相结合,为解决这些问题提供了一种全新的方法。遗传和生化测量技术的尖端技术与极其庞大和成熟的心脏病生物医学调查(“流行病学研究”)的深度整合将产生前所未有的力量和细节相结合的研究。特别是,对于5万名心脏病患者和5万名对照者,我们已经记录了每个参与者的大量细节:-基因组成(例如,多达100万个基因变异或“字母”)-血液生化(例如,多达几百个分析物)-生活方式和其他习惯(例如,饮食,体育活动,烟草和酒精消费)。在这些参与者中信息最丰富的子集中,我们将进行最先进的测量,以补充这一广泛的现有信息。被称为“脂质组学”和“代谢组学”的血液测量方法的一个关键优势应该是,尽管它们涉及的生化过程可能与心脏病发作的原因相关(即分别是脂肪和糖的代谢),但它们的科学研究范围很广。这将避免过早地对可能出现的与心脏病相关的确切因素的身份进行假设。此外,由于在我们的一项研究(我们与一项新发2型糖尿病的研究共享)中,15,000名“对照”参与者的“脂质组学”和“代谢组学”分析已经获得了资助,我们将通过在新发心脏病患者中同时进行相同的分析,实现重大的科学协同效应和成本节约。为了帮助我们以严谨和有原则的方式获取复杂而丰富的研究数据,我们的团队包括世界生物统计学领域的领导者。我们将以我们以前开发的创新方法为基础,帮助区分心脏病的因果因素和非因果因素。其目标是发现心脏病的全新病因,并评估已经被怀疑与心脏病有关的各种因素,如血脂、糖代谢、“炎症”(身体对损伤的反应)和营养因素。我们将使用相同的数据库(辅以其他信息来源)来开发和测试一系列有可能改进对首发心脏病的预测的方法,例如:-最大限度地提高心脏病预测的准确性,例如包含遗传和生化信息的详细分数,这些信息可能与考虑终生预防性治疗的年轻人或具有强烈心脏病家族史的人特别相关-促进保健服务的效率,例如“顺序”筛查,最初涉及对每个人进行相对简单的检查;然后将更昂贵和详细的测量集中在最初确定的最有可能从进一步评估中受益的个人身上。
英文摘要
If medical studies can reliably demonstrate that a particular factor is relevant to heart disease, then this could have important implications for the prediction and prevention of disease, as, for example, is now the case with measurement and modification of blood LDL("bad")-cholesterol levels.Unfortunately, attempts using conventional approaches to identify risk factors that have cause-and-effect relationships with heart disease have often yielded costly failures in drug trials of new medicines. Similarly, only modest improvements have been achieved in the prediction of heart disease with incremental modifications to conventional approaches.Our research plan offers a fundamentally new approach to address these problems by combining the precision of molecular measurements with the power of large-scale population health studies. The deep integration of cutting-edge technologies for genetic and biochemical measurement technologies with extremely large and mature biomedical surveys ("epidemiological studies") of heart disease will yield studies that combine unprecedented power and detail. In particular, for 50,000 people with heart attacks and 50,000 controls, we have for each participant, already recorded extensive detail about: -genetic make-up (eg, up to one million genetic variants or "letters")-blood biochemistry (eg, up to a few hundred analytes)-lifestyle and other habits (eg, diet, physical activity, tobacco and alcohol consumption).In the most informative subsets of these participants, we will conduct state-of-the-art measurements to supplement this extensive existing information. A key advantage of blood measurement methods called "lipidomics" and "metabonomics" should be that, although they relate to biochemical processes likely to be relevant to the causation of heart attacks (ie, fat and sugar metabolism, respectively), they cast wide scientific nets. This should avoid premature assumptions about the identity of the precise factors that might emerge to be relevant to heart disease. Furthermore, as funding has already been awarded for "lipidomics" and "metabonomics" assays in 15,000 "control" participants in one of our studies (which we share with a study of new-onset type 2 diabetes), we will achieve major scientific synergy and cost savings by conducting concurrently the same assays in patients with new onset heart disease.To help harvest the complex and rich data that will emerge from our studies in a rigorous and principled manner, our team includes world leaders in biostatistics. We will build on innovative approaches that we have previously developed to help distinguish causal from non-causal factors in heart disease. The objective will be to discover entirely new causes of heart disease as well as to evaluate a variety of factors already suspected in heart disease, such as blood fats, sugar metabolism, "inflammation" (which is the body's response to injury), and nutritional factors. We will use the same databases (supplemented by additional sources of information) to develop and test a range of approaches that have potential to improve the prediction of first-onset heart disease, such as those that: -maximise accuracy of the prediction of heart disease, such as detailed scores containing genetic and biochemical information, which may be especially relevant to young people contemplating a lifetime of preventive therapy or to people with a strong family history of heart disease-promote efficiency for health services, eg, "sequential" screening, which initially involves comparatively simple tests for everyone, then focusing more costly and detailed measurements on individuals initially identified as being most likely to benefit from further assessment.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
Genomic risk score offers predictive performance comparable to clinical risk factors for ischaemic stroke
基因组风险评分提供的预测性能可与缺血性中风的临床危险因素相媲美
DOI: 10.1101/689935
发表时间: 2019
期刊:
影响因子: --
作者: [Abraham G]
通讯作者: Abraham G
Author Correction: Genomic risk score offers predictive performance comparable to clinical risk factors for ischaemic stroke.
作者更正:基因组风险评分提供的预测性能与缺血性中风的临床风险因素相当。
DOI: 10.1038/s41467-020-14717-y
发表时间: 2020
期刊: Nature communications
影响因子: 16.6
作者: [Abraham G]
通讯作者: Abraham G
DOI: 10.1371/journal.pbio.3001255
发表时间: 2021-11
期刊: PLoS biology
影响因子: 9.8
作者: [Agrawal N, Lawler K, Davidson CM, Keogh JM, Legg R, INTERVAL, Barroso I, Farooqi IS, Brand AH]
通讯作者: Brand AH
DOI: 10.1161/strokeaha.120.032619
发表时间: 2021-08
期刊: Stroke
影响因子: 8.3
作者: [Abraham G, Rutten-Jacobs L, Inouye M]
通讯作者: Inouye M
Molecules to Health Records
  • 批准号:
    HDR-23007
  • 项目类别:
    Intramural
  • 资助金额:
    $762.35万
  • 财政年份:
    2023
  • 负责人:
    John Danesh
  • 依托单位:
Building a comprehensive aortic aneurysm and dissection prediction model incorporating genetic and non-genetic factors
  • 批准号:
    MR/T023783/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $34.79万
  • 财政年份:
    2019
  • 负责人:
    John Danesh
  • 依托单位:
Cambridge Alliance to Protect Bangladesh from Long-term Environmental Hazards (CAPABLE)
  • 批准号:
    MR/P02811X/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $1036.46万
  • 财政年份:
    2017
  • 负责人:
    John Danesh
  • 依托单位:
Study of the interplay of genetic, biochemical, and lifestyle factors on coronary heart disease incidence
  • 批准号:
    G0800270/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $379.35万
  • 财政年份:
    2010
  • 负责人:
    John Danesh
  • 依托单位:
国内基金
海外基金
基于热量传递的传统固态发酵过程缩小(Scale-down)机理及调控
  • 批准号:
    22108101
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    靳光远
  • 依托单位:
基于Multi-Scale模型的轴流血泵瞬变流及空化机理研究
  • 批准号:
    31600794
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    22.0万元
  • 批准年份:
    2016
  • 负责人:
    荆腾
  • 依托单位:
基于异构医学影像数据的深度挖掘技术及中枢神经系统重大疾病的精准预测
  • 批准号:
    61672236
  • 项目类别:
    面上项目
  • 资助金额:
    64.0万元
  • 批准年份:
    2016
  • 负责人:
    王骏
  • 依托单位:
城镇居民亚健康状态的评价方法学及健康管理模式研究
  • 批准号:
    81172775
  • 项目类别:
    面上项目
  • 资助金额:
    14.0万元
  • 批准年份:
    2011
  • 负责人:
    许军
  • 依托单位: